ALLO
Allogene Therapeutics, Inc.$2.21-0.04 (-1.78%)Prev Close$2.25·MCap$563.3M·P/E—·Vol2.82M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
14
$637.2K
◆
Net Activity
Net Seller
$637.2K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Allogene Therapeutics, Inc. (ALLO) has been exclusively selling, with 0 insider purchases totaling $0.00 and 14 insider sales totaling $637.2K. The most recent insider transaction was by Yoshiyama Annie (officer: SVP, Finance), who sold $22.1K worth of shares on Apr 23, 2026. Allogene Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $563.3M.
ALLO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Yoshiyama Annie | officer: SVP, Finance | Sell | 9,586 | $2.31 | $22.1K | 124,517 |
| Apr 2, 2026 | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 2,867 | $2.50 | $7.2K | 195,338 |
| Mar 18, 2026 | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 4,835 | $2.47 | $11.9K | 198,205 |
| Mar 18, 2026 | Chang David D | director, officer: President and CEO | Sell | 47,763 | $2.47 | $118.0K | 5,150,599 |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 0 |
| Feb 2, 2026 | Chang David D | President and CEO | Sell | 95,269 | $1.80 | $171.5K | 0 |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 0 |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 0 |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 0 |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 0 |
| Jan 21, 2026 | Roberts Zachary | EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 0 |
| Nov 17, 2025 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 786 | $1.22 | $958.92 | 0 |
| Oct 21, 2025 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,744 | $1.26 | $46.2K | 0 |
| Jun 10, 2025 | MESSEMER DEBORAH M. | Director | Sell | 36,885 | $1.42 | $52.4K | 0 |
| Apr 21, 2025 | Yoshiyama Annie | SVP, Finance | Sell | 9,601 | $1.41 | $13.5K | 0 |
| Mar 14, 2025 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5,488 | $1.97 | $10.8K | 0 |
| Mar 14, 2025 | Chang David D | President and CEO | Sell | 46,668 | $1.96 | $91.5K | 0 |
| Feb 18, 2025 | MESSEMER DEBORAH M. | Director | Sell | 13,313 | $2.43 | $32.4K | 0 |
| Feb 3, 2025 | Chang David D | President and CEO | Sell | 46,003 | $1.68 | $77.3K | 0 |
| Feb 3, 2025 | Douglas Earl Martin | SVP, General Counsel | Sell | 6,404 | $1.71 | $11.0K | 0 |
| Feb 3, 2025 | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 14,746 | $1.71 | $25.2K | 0 |
| Feb 3, 2025 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 4,361 | $1.73 | $7.5K | 0 |
| Feb 3, 2025 | Roberts Zachary | EVP of R&D | Sell | 18,832 | $1.70 | $32.0K | 0 |
| Jan 21, 2025 | Roberts Zachary | EVP of R&D | Sell | 27,199 | $1.78 | $48.4K | 0 |
| Dec 9, 2024 | MESSEMER DEBORAH M. | Director | Sell | 9,136 | $2.18 | $19.9K | 0 |
| Dec 5, 2024 | Humer Franz B | Director | Sell | 9,221 | $2.16 | $19.9K | 0 |
| Oct 21, 2024 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,404 | $2.84 | $103.4K | 0 |
| Aug 21, 2024 | Douglas Earl Martin | SVP, General Counsel | Sell | 28,310 | $2.79 | $78.8K | 0 |
| Jun 18, 2024 | MESSEMER DEBORAH M. | Director | Sell | 18,641 | $2.28 | $42.5K | 0 |
| May 30, 2024 | Humer Franz B | Director | Sell | 11,200 | $2.34 | $26.2K | 0 |
| May 16, 2024 | Belldegrun Arie | Director | Buy | 1,724,137 | $2.90 | $5.00M0.7% OS | 0 |
| Apr 22, 2024 | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 17,360 | $3.47 | $60.2K | 0 |
| Mar 14, 2024 | Chang David D | President and CEO | Sell | 53,393 | $4.33 | $231.2K | 0 |
| Jan 30, 2024 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Buy | 190 | $3.59 | $683.05 | 0 |
| Jan 22, 2024 | Roberts Zachary | EVP of R&D | Sell | 24,690 | $3.17 | $78.4K | 0 |
| Dec 18, 2023 | MESSEMER DEBORAH M. | Director | Sell | 18,640 | $2.70 | $50.3K | 0 |
| Aug 7, 2023 | Mayo Stephen | Director | Sell | 10,000 | $4.29 | $42.9K | 0 |
| Mar 14, 2023 | Bhavnagri Veer | General Counsel | Sell | 23,628 | $5.67 | $134.0K | 0 |
| Mar 14, 2023 | Chang David D | President and CEO | Sell | 22,340 | $5.56 | $124.2K | 0 |
| Mar 14, 2023 | MOORE ALISON | Chief Technical Officer | Sell | 8,351 | $5.51 | $46.0K | 0 |
| Mar 14, 2023 | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 35,879 | $5.47 | $196.3K | 0 |
| Feb 13, 2023 | Bhavnagri Veer | General Counsel | Sell | 3,000 | $6.85 | $20.6K | 0 |
| Jan 17, 2023 | Bhavnagri Veer | General Counsel | Sell | 3,000 | $7.04 | $21.1K | 0 |
| Dec 15, 2022 | Bhavnagri Veer | General Counsel | Sell | 5,602 | $7.53 | $42.2K | 0 |
| Oct 7, 2022 | Amado Rafael | EVP of R&D | Sell | 8,464 | $11.83 | $100.1K | 0 |
| Oct 3, 2022 | Amado Rafael | EVP of R&D | Sell | 8,968 | $11.06 | $99.2K | 0 |
| Aug 11, 2022 | WITTE OWEN N. | Director | Sell | 15,000 | $16.75 | $251.3K | 0 |
| Aug 2, 2022 | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.97 | $23.9K | 0 |
| Jul 5, 2022 | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.44 | $22.9K | 0 |
| Jun 22, 2022 | WITTE OWEN N. | Director | Sell | 10,000 | $11.76 | $117.6K | 0 |
Showing 1–50 of 75
1 / 2
ALLO Insider Buying Activity
The following table shows recent insider purchases of Allogene Therapeutics, Inc. (ALLO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 16, 2024 | Belldegrun Arie | Director | Buy | 1,724,137 | $2.90 | $5.00M0.7% OS | 0 |
| Jan 30, 2024 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Buy | 190 | $3.59 | $683.05 | 0 |
ALLO Insider Selling Activity
The following table shows recent insider sales of Allogene Therapeutics, Inc. (ALLO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Yoshiyama Annie | officer: SVP, Finance | Sell | 9,586 | $2.31 | $22.1K | 124,517 |
| Apr 2, 2026 | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 2,867 | $2.50 | $7.2K | 195,338 |
| Mar 18, 2026 | Beneski Benjamin Machinas | officer: SVP, Chief Technical Officer | Sell | 4,835 | $2.47 | $11.9K | 198,205 |
| Mar 18, 2026 | Chang David D | director, officer: President and CEO | Sell | 47,763 | $2.47 | $118.0K | 5,150,599 |
| Feb 2, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 7,549 | $1.73 | $13.1K | 0 |
| Feb 2, 2026 | Chang David D | President and CEO | Sell | 95,269 | $1.80 | $171.5K | 0 |
| Feb 2, 2026 | Douglas Earl Martin | SVP, General Counsel | Sell | 22,900 | $1.76 | $40.3K | 0 |
| Feb 2, 2026 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 24,001 | $1.76 | $42.2K | 0 |
| Feb 2, 2026 | Roberts Zachary | EVP of R&D | Sell | 35,700 | $1.77 | $63.2K | 0 |
| Feb 2, 2026 | Yoshiyama Annie | SVP, Finance | Sell | 4,167 | $1.72 | $7.2K | 0 |
| Jan 21, 2026 | Roberts Zachary | EVP of R&D | Sell | 26,269 | $1.56 | $41.0K | 0 |
| Nov 17, 2025 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 786 | $1.22 | $958.92 | 0 |
| Oct 21, 2025 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,744 | $1.26 | $46.2K | 0 |
| Jun 10, 2025 | MESSEMER DEBORAH M. | Director | Sell | 36,885 | $1.42 | $52.4K | 0 |
| Apr 21, 2025 | Yoshiyama Annie | SVP, Finance | Sell | 9,601 | $1.41 | $13.5K | 0 |
| Mar 14, 2025 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | 5,488 | $1.97 | $10.8K | 0 |
| Mar 14, 2025 | Chang David D | President and CEO | Sell | 46,668 | $1.96 | $91.5K | 0 |
| Feb 18, 2025 | MESSEMER DEBORAH M. | Director | Sell | 13,313 | $2.43 | $32.4K | 0 |
| Feb 3, 2025 | Chang David D | President and CEO | Sell | 46,003 | $1.68 | $77.3K | 0 |
| Feb 3, 2025 | Douglas Earl Martin | SVP, General Counsel | Sell | 6,404 | $1.71 | $11.0K | 0 |
| Feb 3, 2025 | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 14,746 | $1.71 | $25.2K | 0 |
| Feb 3, 2025 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 4,361 | $1.73 | $7.5K | 0 |
| Feb 3, 2025 | Roberts Zachary | EVP of R&D | Sell | 18,832 | $1.70 | $32.0K | 0 |
| Jan 21, 2025 | Roberts Zachary | EVP of R&D | Sell | 27,199 | $1.78 | $48.4K | 0 |
| Dec 9, 2024 | MESSEMER DEBORAH M. | Director | Sell | 9,136 | $2.18 | $19.9K | 0 |
| Dec 5, 2024 | Humer Franz B | Director | Sell | 9,221 | $2.16 | $19.9K | 0 |
| Oct 21, 2024 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | 36,404 | $2.84 | $103.4K | 0 |
| Aug 21, 2024 | Douglas Earl Martin | SVP, General Counsel | Sell | 28,310 | $2.79 | $78.8K | 0 |
| Jun 18, 2024 | MESSEMER DEBORAH M. | Director | Sell | 18,641 | $2.28 | $42.5K | 0 |
| May 30, 2024 | Humer Franz B | Director | Sell | 11,200 | $2.34 | $26.2K | 0 |
| Apr 22, 2024 | MOORE TIMOTHY L. | Chief Technical Officer | Sell | 17,360 | $3.47 | $60.2K | 0 |
| Mar 14, 2024 | Chang David D | President and CEO | Sell | 53,393 | $4.33 | $231.2K | 0 |
| Jan 22, 2024 | Roberts Zachary | EVP of R&D | Sell | 24,690 | $3.17 | $78.4K | 0 |
| Dec 18, 2023 | MESSEMER DEBORAH M. | Director | Sell | 18,640 | $2.70 | $50.3K | 0 |
| Aug 7, 2023 | Mayo Stephen | Director | Sell | 10,000 | $4.29 | $42.9K | 0 |
| Mar 14, 2023 | Bhavnagri Veer | General Counsel | Sell | 23,628 | $5.67 | $134.0K | 0 |
| Mar 14, 2023 | Chang David D | President and CEO | Sell | 22,340 | $5.56 | $124.2K | 0 |
| Mar 14, 2023 | MOORE ALISON | Chief Technical Officer | Sell | 8,351 | $5.51 | $46.0K | 0 |
| Mar 14, 2023 | SCHMIDT ERIC THOMAS | Chief Financial Officer | Sell | 35,879 | $5.47 | $196.3K | 0 |
| Feb 13, 2023 | Bhavnagri Veer | General Counsel | Sell | 3,000 | $6.85 | $20.6K | 0 |
| Jan 17, 2023 | Bhavnagri Veer | General Counsel | Sell | 3,000 | $7.04 | $21.1K | 0 |
| Dec 15, 2022 | Bhavnagri Veer | General Counsel | Sell | 5,602 | $7.53 | $42.2K | 0 |
| Oct 7, 2022 | Amado Rafael | EVP of R&D | Sell | 8,464 | $11.83 | $100.1K | 0 |
| Oct 3, 2022 | Amado Rafael | EVP of R&D | Sell | 8,968 | $11.06 | $99.2K | 0 |
| Aug 11, 2022 | WITTE OWEN N. | Director | Sell | 15,000 | $16.75 | $251.3K | 0 |
| Aug 2, 2022 | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.97 | $23.9K | 0 |
| Jul 5, 2022 | Amado Rafael | EVP of R&D and CMO | Sell | 2,000 | $11.44 | $22.9K | 0 |
| Jun 22, 2022 | WITTE OWEN N. | Director | Sell | 10,000 | $11.76 | $117.6K | 0 |
ALLO Insiders
Similar Stocks to ALLO
VRTX
Vertex Pharmaceuticals Incorporated
$428.36+0.55%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$739.29-0.68%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$305.75-0.85%
$41.24B
INSM
Insmed Incorporated
$133.16-2.19%
$30.79B
RVMD
Revolution Medicines, Inc.
$145.59+10.58%
$29.51B
UTHR
United Therapeutics Corporation
$566.37-0.28%
$25.13B
MRNA
Moderna, Inc.
$46.93-3.64%
$21.42B
RPRX
Royalty Pharma plc
$49.63-0.02%
$21.20B